CSBR earnings date and last-quarter result: next report 2026-07-27, last quarter miss, P/E -37.79. Updated 2026-07-23.
Champions Oncology (CSBR) Research Hub
Champions Oncology (CSBR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 4.86 USD (+2.97%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -37.79, market cap 0.08B. This hub links to the full technical, earnings and options research available for CSBR.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 4.86 USD (+2.97%) |
| 52-week range | 4.63 USD – 7 USD |
| Trend regime | Range |
| 14-day RSI | 43.6 (Bearish) |
| Trailing P/E | -37.79 |
| Market cap | 0.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-27 |
Available research for CSBR
Covered Call on CSBR: how it works, illustrative setup around the real 4.86 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CSBR: how it works, illustrative setup around the real 4.86 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CSBR: how it works, illustrative setup around the real 4.86 USD price, max profit/loss, breakeven and when to use it. Educational.
CSBR technical analysis: range, last 4.86 USD, RSI 43.6, 52w range 4.63 USD–7 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CSBR in?
Champions Oncology (CSBR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CSBR in an uptrend or downtrend?
As of 2026-10-26, CSBR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CSBR's trailing P/E ratio?
CSBR's trailing P/E is -37.79, with a market cap of 0.08B. See the earnings research page for full valuation detail.
When does CSBR next report earnings?
CSBR is next scheduled to report earnings on 2026-07-27.